/ANEB
ANEB Stock - Anebulo Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$2.17-1.81%
$0.04 (-1.81%) • Dec 19
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.53
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+176.5%upside
Target: $6.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ANEB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.15 – $2.19
TARGET (TP)$6.00
STOP LOSS$2.00
RISK/REWARD1:22.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.87
52W High$3.42
52W Low$0.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-9,223,481 | $-8,309,000 | $-11,783,599 | $-6,831,174 | $-3,614,000 |
| Net Income | $-8,484,763 | $-8,202,000 | $-11,732,338 | $-6,825,619 | $-30,253,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.25 | $-0.32 | $-0.47 | $-0.29 | $-1.30 |
Company Overview
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ANEBBeat Rate
47%
Last 17 quarters
Avg Surprise
-303.7%
EPS vs Estimate
Beats / Misses
8/7
2 met exactly
Latest EPS
$-0.05
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.11vs$-0.11
Q2 24
+45.5%
$-0.06vs$-0.11
Q3 24
+61.5%
$-0.05vs$-0.13
Q4 24
-60.0%
$-0.08vs$-0.05
Q1 25
-12.5%
$-0.09vs$-0.08
Q2 25
+20.0%
$-0.04vs$-0.05
Q3 25
+23.1%
$-0.05vs$-0.07
Q4 25
+58.3%
$-0.05vs$-0.12
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.12 | $-0.05 | +58.3% | ✓ BEAT |
Q3 2025 | Sep 29, 2025 | $-0.07 | $-0.05 | +23.1% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Q1 2025 | Feb 14, 2025 | $-0.08 | $-0.09 | -12.5% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.05 | $-0.08 | -60.0% | ✗ MISS |
Q3 2024 | Sep 25, 2024 | $-0.13 | $-0.05 | +61.5% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.11 | $-0.06 | +45.5% | ✓ BEAT |
Q1 2024 | Feb 13, 2024 | $-0.11 | $-0.11 | 0.0% | = MET |
Q4 2023 | Nov 14, 2023 | $-0.11 | $-0.10 | +9.1% | ✓ BEAT |
Q3 2023 | Sep 20, 2023 | $-0.10 | $-0.10 | 0.0% | = MET |
Q2 2023 | May 11, 2023 | $-0.16 | $-0.11 | +31.3% | ✓ BEAT |
Q1 2023 | Feb 10, 2023 | $-0.11 | $-0.15 | -36.4% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.10 | $-0.11 | -10.0% | ✗ MISS |
Q3 2022 | Sep 9, 2022 | $-0.07 | $-0.10 | -42.9% | ✗ MISS |
Q2 2022 | May 11, 2022 | $-0.05 | $-0.08 | -60.0% | ✗ MISS |
Q1 2022 | Feb 11, 2022 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | — | $-0.07 | — | — |
Q3 2021 | Sep 22, 2021 | $-0.00 | $-0.13 | -5206.1% | ✗ MISS |
Latest News
Anebulo Pharmaceuticals Q1 EPS $(0.05) Beats $(0.12) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 09:33 PM
Anebulo Pharmaceuticals Q4 EPS $(0.05) Beats $(0.08) Estimate
📈 PositiveBenzinga•Sep 29, 2025, 08:12 PM
Anebulo Pharmaceuticals Doses First Patients In Phase 1 Single Ascending Dose Study Of Intravenous Selonabant For Acute Cannabis-Induced Toxicity
📈 PositiveBenzinga•Sep 25, 2025, 11:33 AM
Anebulo Pharmaceuticals shares are trading higher after the company announced the board will review all strategic alternatives.
📈 PositiveBenzinga•Sep 12, 2025, 12:42 PM
Anebulo Pharmaceuticals Weighs Going Private As Board Reviews Strategic Alternatives
➖ NeutralBenzinga•Sep 12, 2025, 11:32 AM
Anebulo approves reverse stock split ahead of going-private transaction
📉 NegativeSeeking Alpha•Jul 23, 2025, 06:58 PM
Frequently Asked Questions about ANEB
What is ANEB's current stock price?
Anebulo Pharmaceuticals, Inc. (ANEB) is currently trading at $2.17 per share. The stock has moved -1.81% today.
What is the analyst price target for ANEB?
The average analyst price target for ANEB is $6.00, based on 1 analyst.
What sector is Anebulo Pharmaceuticals, Inc. in?
Anebulo Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ANEB's market cap?
Anebulo Pharmaceuticals, Inc. has a market capitalization of $0.09 billion, making it a small-cap company.
Does ANEB pay dividends?
No, Anebulo Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLNN
Clene Inc.
$6.68
Mkt Cap: $0.1B
COYA
Coya Therapeutics, Inc.
$5.49
Mkt Cap: $0.1B
ESLA
Estrella Immunopharma, Inc.
$1.69
Mkt Cap: $0.1B
IMMX
Immix Biopharma, Inc.
$5.72
Mkt Cap: $0.2B
MGNX
MacroGenics, Inc.
$1.50
Mkt Cap: $0.1B
OKYO
OKYO Pharma Limited
$2.03
Mkt Cap: $0.1B
PLRX
Pliant Therapeutics, Inc.
$1.23
Mkt Cap: $0.1B
TLSA
Tiziana Life Sciences Ltd
$1.52
Mkt Cap: $0.1B
WHWK
Whitehawk Therapeutics Inc
$2.56
Mkt Cap: $0.1B
ZNTL
Zentalis Pharmaceuticals, Inc.
$1.40
Mkt Cap: $0.1B
Explore stocks similar to ANEB for comparison